Carlos L. Arteaga
Affiliations: | Vanderbilt University, Nashville, TN |
Area:
Cell Biology, Oncology, Molecular BiologyGoogle:
"Carlos Arteaga"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Lin CC, Chang TC, Wang Y, et al. (2024) PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Nature Communications. 15: 2287 |
| Connolly RM, Wang V, Hyman DM, et al. (2024) Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. OF1-OF8 |
| Li Z, Metzger Filho O, Viale G, et al. (2024) HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial. The Journal of Clinical Investigation |
| Marquez-Palencia M, Reza Herrera L, Parida PK, et al. (2024) AXL/WRNIP1 mediates replication stress response and promotes therapy resistance and metachronous metastasis in HER2+ breast cancer. Cancer Research |
| Xu Y, Wang Z, Sjöström M, et al. (2023) ZNF397 Loss Triggers TET2-driven Epigenetic Rewiring, Lineage Plasticity, and AR-targeted Therapy Resistance in AR-dependent Cancers. Biorxiv : the Preprint Server For Biology |
| Lin CC, Chang TC, Wang Y, et al. (2023) Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Research Square |
| Marin A, Mamun AA, Patel H, et al. (2023) Acquired secondary HER2 mutations enhance HER2/MAPK signaling and promote resistance to HER2 kinase inhibition in breast cancer. Cancer Research |
| Liu S, Xie SM, Liu W, et al. (2023) Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. Breast Cancer Research : Bcr. 25: 62 |
| Kumar A, Ramani V, Bharti V, et al. (2023) Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses. Journal For Immunotherapy of Cancer. 11 |
| Clark AS, Hong F, Finn RS, et al. (2023) Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. OF1-OF7 |